转录组分析确定了PMM2-CDG中的失调路径和治疗点
Diana Gallego1, Mercedes Serrano2, Jose Cordoba-Caballero3
1Centro de Diagnóstico de Enfermedades Moleculares, Centro de Biología Molecular-SO UAM-CSIC, Universidad Autónoma de Madrid, Campus de Cantoblanco, U746- CIBER de Enfermedades Raras (CIBERER), Instituto de Investigación Sanitaria IdiPAZ, 28049 Madrid, Spain.
Biochimica et biophysica acta. Molecular basis of disease
|April 10, 2024
概括
基化2-先天性疾病 (PMM2-CDG) 涉及细胞通路缺陷. 转录组分析确定了潜在的治疗点,并强调了炎症在PMM2-CDG中的作用.
科学领域:
- 生物化学和分子生物学
- 遗传学和基因组学 遗传学和基因组学
- 细胞生物学 细胞生物学
背景情况:
- PMM2-CDG是最常见的血糖化先天性疾病,由胺转基因酶2 (PMM2) 缺乏引起.
- 这是一种多系统性疾病,严重程度可变,特别影响神经系统,但其分子病理生理学尚不清楚.
- 目前没有有效的治疗方法可用于PMM2-CDG.
研究的目的:
- 通过使用患者衍生纤维细胞,了解PMM2-CDG症状的基础分子机制.
- 为了确定PMM2-CDG的潜在可用药的目标.
- 探索细胞通路和炎症反应在疾病中的作用.
主要方法:
- 基于RNA测序 (RNA-seq) 的转录组研究,对患者衍生纤维细胞进行.
- 系统生物学方法用于识别受影响的细胞通路 (衰老,骨调节,细胞粘附,细胞外矩阵 (ECM),对细胞因子的反应).
- 功能验证试验包括细胞增殖,细胞周期,ECM组成和细胞迁移评估.
主要成果:
- 转录组分析揭示了失调的途径,包括衰老,骨调节,细胞粘附,ECM和细胞因子反应.
- 功能性测试证实了患者纤维细胞的细胞增殖,细胞周期,ECM组成和细胞迁移的缺陷.
- 炎症反应与疾病病理生理学有关,而药理伴随者部分逆转了基因表达变化.
结论:
- 转录组数据为确定PMM2-CDG的治疗点提供了一个平台.
- 该研究突出了潜在的治疗策略,包括药理伴侣和曼诺-1-P用于药物重新用途.
- 了解分子病理生理学对于开发有效的治疗方法和监测治疗疗效至关重要.
相关概念视频
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...